10:30am Manufacturing PMI
Despite falling from December’s two-year
record of 54.5 to 52.9, the headline HSBC India Purchasing Managers’ Index
(PMI) remained consistent with a solid improvement in business conditions in
January.
PMI is a seasonally adjusted indicator
designed to give an accurate overview of manufacturing operating conditions.
Moreover, the latest expansion was the
fifteenth in as many months. Sector data highlighted consumer goods as the best
performing of the three market groups for the third month in a row, says HSBC
in its report.
"Manufacturing activity continued
to signal improvement in January, though the rate of growth slipped to a
three-month low. The slip can partly be attributed to consolidation after two
months of impressive upticks," said Pranjul Bhandari, Chief India Economist
at HSBC.
"New orders, both from domestic
and international sources, also continued to grow, though at a slower pace than
in December. New orders were strongest in the consumer goods sector. On the
inflation front, growth in input and output prices moderated further due to
cheaper commodity prices," he added.
"Sluggish growth and falling
inflation further reinforces our view that the RBI should deliver upfront rate
cuts. We expect the repo rate to be lowered by 75bp in the first half of
2015," said Pranjul.
10:00am Market Check
The market remained under pressure amid
consolidation following weakness in Asian equities post China data. The Sensex
fell 73.99 points to 29108.96 and the Nifty declined 16.30 points at 8792.60.
The broader markets outperformed
benchmarks with the BSE Midcap and Smallcap indices gaining 0.6 percent each.
About 1230 shares have advanced, 708 shares declined, and 195 shares are
unchanged.
Sun Pharma gained more than 2 percent
and Ranbaxy jumped over 3.5 percent to hit record highs. The US Federal Trade
Commission approved the pharma major’s plan to buy Ranbaxy on the condition
that it divests one antibiotic product to avoid anti-competitive impact in the
US market. Torrent Pharma will acquire Ranbaxy's minocycline business in the
US.